| 2026-08-13 | Press release | Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-13 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-06 | Press release | Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call |
| 2026-07-30 | Press release | Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Prac |
| 2026-07-15 | 8-K | Form 8-K, Item 7.01 |
| 2026-07-15 | 8-K | Form 8-K/A, Item 7.01 |
| 2026-07-14 | Deck | Corporate Presentation - July 2026 |
| 2026-07-14 | Press release | Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2- PIK3CA Wild-Type Locally Adv |
| 2026-06-08 | 8-K | Form 8-K, Item 1.01 |
| Transcript | Earnings call transcript |
| 2026-06-03 | Press release | Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 |
| 2026-06-03 | Press release | Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032 |
| 2026-06-02 | Deck | Celcuity Investor Conference Call Presentation |
| 2026-06-02 | Press release | Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Comp |
| 2026-06-02 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-01 | Press release | Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Tria |
| 2026-05-28 | Press release | Celcuity To Participate in Upcoming Investor Conferences |
| 2026-05-20 | 8-K | Form 8-K/A, Item 5.02 |
| 2026-05-18 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-15 | Transcript | Q1 FY26 earnings call transcript |
| 2026-05-14 | Press release | Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expand |
| 2026-05-14 | Press release | Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-14 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-14 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-07 | Press release | Press release · Q1 2026 · May 2026 |
| 2026-05-01 | Press release | Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free |
| 2026-05-01 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-02 | Proxy | Definitive proxy statement |
| 2026-03-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-26 | Transcript | Q4 FY25 earnings call transcript |
| 2026-03-25 | Press release | Press release · FY 2025 · Mar 2026 |
| 2026-03-25 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-18 | Press release | Press release · FY 2025 · Mar 2026 |
| 2026-03-09 | Press release | Press release · Mar 2026 |
| 2026-02-25 | Press release | Press release · Feb 2026 |
| 2026-02-12 | Press release | Press release · Feb 2026 |
| 2026-02-12 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-04 | Press release | Press release · Feb 2026 |
| 2026-01-20 | Press release | Press release · Jan 2026 |